Monitoring Multiple Myeloma

  Abstract:  Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated plasma cells. MM is a slowly growing, […]

Incorporating Monoclonal Antibodies Into the Management of Multiple Myeloma

  H&O  How do monoclonal antibodies work? TM  Monoclonal antibodies are immunoglobulins (Igs) that are generated and manufactured to target a specific antigen present on a […]

The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma

  Abstract:  Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments. Certain molecular abnormalities confer […]

When to Initiate Treatment in Smoldering Multiple Myeloma

  H&O  How is smoldering multiple myeloma defined? MM  Smoldering multiple myeloma is a plasma cell dis­order defined by the presence of a serum monoclonal component […]

The Role of Autologous Stem Cell Transplant in Patients With Multiple Myeloma

  H&O  What are the clinical characteristics of multiple myeloma? JM  Multiple myeloma has historically been defined by 4 clinical characteristics: elevated calcium, renal deficiency, anemia, […]

Use of Genetic Markers in Multiple Myeloma

  H&O  In what ways is multiple myeloma a genetically heterogeneous disease? RF  In an editorial written several years ago, I referred to this disease as […]

Myeloma Bone Disease: Pathogenesis and Treatment

  Abstract: Bone involvement manifesting as osteolytic bone disease (OBD) or osteopenia is one of the defining features of multiple myeloma (MM). Osteolytic lesions develop in […]

Monoclonal Antibodies in Multiple Myeloma: Data From the 2015 ASH Meeting

H&O What are the most important principles in the management of multiple myeloma? SL In the past few years, treatment options for myeloma have increased and […]